You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Durvalumab

Showing 1 - 25 of 671
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Mesothelioma Trial in Durham, Houston (Durvalumab / tremelimumab, Platinum cisplatin or carboplatin and pemetrexed chemo plus

Not yet recruiting
  • Mesothelioma
  • Durvalumab / tremelimumab
  • Platinum cisplatin or carboplatin and pemetrexed chemotherapy plus durvalumab/tremelimumab
  • Durham, North Carolina
  • +1 more
Jul 5, 2023

NSCLC Trial (Durvalumab)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Durvalumab
  • (no location specified)
Jun 22, 2023

BCLC A Hepatocellular Carcinoma Non-resectable and Not Amenable for RFA Trial in Bobigny (Durvalumab/Tremelimumab in neoadjuvant

Not yet recruiting
  • BCLC A Hepatocellular Carcinoma Non-resectable and Not Amenable for RFA
  • Durvalumab/Tremelimumab in neoadjuvant and Durvalumab in adjuvant setting
  • Bobigny, France
    Hospitl Avicenne
Sep 13, 2023

Biliary Tract Tumors, Gallbladder Cancer, Cholangiocarcinoma Trial in Seoul (Durvalumab + Gem/Cis, Gem/Cis)

Active, not recruiting
  • Biliary Tract Neoplasms
  • +2 more
  • Seoul, Korea, Republic of
    Asan Medical Center
Jan 30, 2023

Unrescetable Hepatocellular Carcinoma Trial in Tianjin (HAIC+Durvalumab+Tremelimumab+Bevacizumab)

Not yet recruiting
  • Unrescetable Hepatocellular Carcinoma
  • Tianjin, Tianjin, China
    Tianjin Cancer Hospital Airport Hospital
May 16, 2023

Durvalumab, Intrahepatic Cholangiocarcinoma, Gemcis Trial in Tianjin (Durvalumab, Surgery, Gemcitabine)

Recruiting
  • Durvalumab
  • +2 more
  • Durvalumab
  • +3 more
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute and Hospital
Jan 3, 2023

Non-Muscle- Invasive Bladder Cancer Trial (Durvalumab, BCG)

Not yet recruiting
  • Non-Muscle- Invasive Bladder Cancer
  • Durvalumab
  • BCG
  • (no location specified)
Jul 5, 2023

Hepatocellular Carcinoma (HCC) Trial (Durvalumab, Bevacizumab, Transarterial Radioembolization (TARE))

Not yet recruiting
  • Hepatocellular Carcinoma (HCC)
  • Durvalumab
  • +2 more
  • (no location specified)
Sep 11, 2023

Advanced Solid Tumours Trial in Beijing (Ceralasertib, Durvalumab)

Not yet recruiting
  • Advanced Solid Tumours
  • Beijing, China
    Research Site
Aug 23, 2022

Metastatic Adult Soft Tissue Sarcoma, Recurrent Adult Soft Tissue Sarcoma Trial in Hannover (Durvalumab and Tremelimumab,

Completed
  • Metastatic Adult Soft Tissue Sarcoma
  • Recurrent Adult Soft Tissue Sarcoma
  • Hannover, Germany
    Medizinische Hochschule Hannover
Jan 18, 2023

Hepatocellular Carcinoma Trial in Munich, Würzburg (durvalumab, tremelimumab, bevacizumab)

Recruiting
  • Hepatocellular Carcinoma
  • durvalumab, tremelimumab, bevacizumab
  • Munich, Germany
  • +2 more
May 3, 2023

Resectable Biliary Tract Cancer Trial in Tianjin (Cisplatin, Gemcitabine, Nab-paclitaxel)

Recruiting
  • Resectable Biliary Tract Cancer
  • Tianjin, Tianjin, China
    Tianjin Cancer Hospital Airport Hospital
Nov 30, 2022

Biliary Tract Tumors, Immunotherapy Trial in Beijing (Durvalumab, Lenvatinib Oral Product, Chemotherapy)

Recruiting
  • Biliary Tract Neoplasms
  • Immunotherapy
  • Durvalumab
  • +2 more
  • Beijing, Beijing, China
    Chinese Academy of Medical Sciences & Peking Union Medical Colle
Jul 6, 2023

NSCLC Trial in Tampa, Philadelphia (Durvalumab, Carboplatin, Abequolixron)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • Durvalumab
  • +4 more
  • Tampa, Florida
  • +1 more
Jun 9, 2023

Fibrolamellar Hepatocellular Carcinoma Trial in Baltimore (Durvalumab, DRP-104)

Not yet recruiting
  • Fibrolamellar Hepatocellular Carcinoma
  • Baltimore, Maryland
    Johns Hopkins SKCCC
Aug 30, 2023

Small Cell Lung Cancer, SCLC, Extensive Stage Small Cell Lung Cancer Trial (Durvalumab, Monalizumab, Carboplatin or Cisplatin)

Not yet recruiting
  • Small Cell Lung Cancer
  • +2 more
  • Durvalumab
  • +3 more
  • (no location specified)
Jun 5, 2023

Borderline Resectable Carcinoma, Biliary Tract Cancer Trial in Washington (Durvalumab, Tremelimumab, Gemcitabine)

Not yet recruiting
  • Borderline Resectable Carcinoma
  • Biliary Tract Cancer
  • Durvalumab
  • +4 more
  • Washington, District of Columbia
    Lombardi Comprehensive Cancer Center, Georgetown University
Aug 24, 2023

Resectable Hepatocellular Carcinoma, Hepatocellular Carcinoma, Hepatocellular Cancer Trial in Boston (Durvalumab, Tremelimumab,

Not yet recruiting
  • Resectable Hepatocellular Carcinoma
  • +2 more
  • Durvalumab
  • +2 more
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
Jan 18, 2023

Biliary Tract Cancers Trial (durvalumab)

Not yet recruiting
  • Biliary Tract Cancers
  • durvalumab
  • (no location specified)
Jun 20, 2023

Lung Cancer Trial (Savolitinib, Durvalumab)

Recruiting
  • Lung Cancer
  • Beijing, China
  • +2 more
Jan 11, 2023

Non Small Cell Lung Cancer, Stage III Non-small-cell Lung Cancer Trial in United States (device, drug, radiation, procedure)

Active, not recruiting
  • Non Small Cell Lung Cancer
  • Stage III Non-small-cell Lung Cancer
  • Durvalumab
  • +4 more
  • Chicago, Illinois
  • +3 more
Jan 18, 2023

Nonsmall Cell Lung Cancer Stage III, Unresectable Non-Small Cell Lung Carcinoma Trial in Winston-Salem (drug, other, diagnostic

Not yet recruiting
  • Nonsmall Cell Lung Cancer Stage III
  • Unresectable Non-Small Cell Lung Carcinoma
  • Durvalumab
  • +3 more
  • Winston-Salem, North Carolina
    Wake Forest Baptist Comprehensive Cancer Center
Jan 12, 2023

Lung Cancer, Gastro-intestinal Cancer Trial in Houston (Durvalumab, Adagrasib)

Not yet recruiting
  • Lung Cancer
  • Gastro-intestinal Cancer
  • Houston, Texas
    M D Anderson Cancer Center
May 9, 2023

Unresectable Intrahepatic Cholangiocarcinoma Trial in Baltimore (Durvalumab, SNDX-6352)

Active, not recruiting
  • Unresectable Intrahepatic Cholangiocarcinoma
  • Baltimore, Maryland
    Sidney Kimmel Comprehensive Cancer Center
Jan 10, 2023

Stomach Cancer, Adenocarcinoma Trial in Seoul (Durvalumab, Savolitinib)

Recruiting
  • Stomach Cancer, Adenocarcinoma
  • Seoul, Korea, Republic of
    Samsung Medical Center
Jan 10, 2023